Sequester Will Hinder Drug, Device Reviews, FDA Head Says

Law360, New York (April 26, 2013, 1:43 PM EDT) -- The U.S. Food and Drug Administration’s top official on Friday warned Congress that the automatic budget cuts known as sequestration could undermine inspections and snarl reviews of new drugs and medical devices, imperiling consumer health and the nation’s economy.

FDA Commissioner Margaret Hamburg, in a 2014 budget hearing before a House Appropriations Committee panel, said insufficient funding could leave the agency ill-equipped to spot potentially harmful merchandise. That, in turn, could shake Americans’ faith in the pharmaceutical and device industries, which are “vital components of the...
To view the full article, register now.